arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Forte Biosciences, Inc.

FBRX
$76.96 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
44 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

Forte Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -13.5% ↗
FCF / Share None
Trailing P/E —
Price / Book 8.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Aug 26, 2026.

44-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.00K
↓ -100.0% —
Net Income Profit after all expenses
$-22.14M
↓ -41.4% —
Long-Term Debt Long-term obligations
$22.08M
↓ -8.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
7
Cash Quality →
50

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 44 quarters